London, England – There are ~7,000 rare diseases that together affect 300 million people. For the vast majority of these patients there are no approved treatments, representing a huge unmet medical need. Advances in the understanding of the molecular basis of rare diseases, the continued development of therapeutic platforms such...
finance News
BOSTON — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “2023 is a very important year for Decibel as we...
BOSTON, Mass. — Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS). Composition of matter covered by these applications aims...
TARRYTOWN, N.Y. — Today, Diabetic Tussin, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes Association® (ADA). This over-the-counter cold and cough...
MOUNTAIN VIEW, Calif. & BOSTON, Mass. — DNAnexus, Inc., the provider of the Precision Health Data Cloud, and TMA Precision Health, a global health platform for rare diseases, today announced a collaboration to advance basic and translational research for patients who have a rare disease. As part of the agreement,...
STAMFORD, Conn. – Dr. James M. Wilson and Alex Karnal announced today the launch of The Institute for Life Changing Medicines, a nonprofit organization, with a mission of identifying, developing and promoting access to therapies that have transformative potential but are not considered commercially viable because they are designed to...
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, reported financial results for the fourth quarter and full year 2022 and business highlights.
Palo Alto, Calif. — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, reported financial results for fourth quarter and full year 2022 and provided a business update. “In December, we announced that both our...
TOKYO & NEW YORK – Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed...
Vancouver, Canada — The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % during the forecast period. Rising frequency of uncommon illnesses and increasing number of governments providing regulatory incentives for development of orphan drugs are...